Lea Peter, Ling Michael
SQI Diagnostics, 36 Meteor Drive, Toronto, Ontario, M9W 1A4, Canada.
Curr Opin Mol Ther. 2008 Jun;10(3):251-9.
Microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Assays encompass immunohistochemistry, fluorescence in situ hybridization, ELISA and sequencing methods that must comply with stringent regulatory specifications. Current test services available range from single-site service-based assays to multi-laboratory testing. Some tests have regulatory approval, whereas others are regulated by the Clinical Laboratory Improvement Act or the College of American Pathologists, or both. Expectations of personalized medicine are building, and the future is expected to bring truly targeted treatments based on test results. In this review, biomarkers, screening, diagnosis, potential prognosis and treatment pertaining to colorectal, breast, and lung cancers are discussed and evaluated. Assay data are expected to improve clinical indices and treatment algorithms, leading to dynamic disease models for real-time, data-modulated patient management.
基于生物标志物的癌症分子诊断和预后检测分析的微阵列多重蛋白质测量注定将成为免疫诊断行业的一个巨大增长领域。检测方法包括免疫组织化学、荧光原位杂交、酶联免疫吸附测定和测序方法，这些方法必须符合严格的监管规范。目前可用的检测服务范围从基于单站点服务的检测到多实验室检测。一些检测已获得监管批准，而其他检测则受《临床实验室改进法案》或美国病理学家学会监管，或两者皆受监管。对个性化医疗的期望正在形成，预计未来将根据检测结果带来真正有针对性的治疗方法。在这篇综述中，讨论并评估了与结直肠癌、乳腺癌和肺癌相关的生物标志物、筛查、诊断、潜在预后和治疗。预计检测数据将改善临床指标和治疗算法，从而形成用于实时、数据调制的患者管理的动态疾病模型。
